Andere Sprachen Rocket Pharmaceuticals, Inc.

Aktien

A2JA9Q

US77313F1066

RCKT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
21,52 ^USD	-1,51 %		-9,08 %	-28,19 %

16.04.	Rocket Pharmaceuticals Insider verkaufte Aktien im Wert von $1,945,785, laut einer aktuellen SEC Einreichung	MT
11.04.	Rocket Pharmaceuticals Insider verkaufte Aktien im Wert von $308,763, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	16.04.
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	11.04.
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	02.04.
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02.04.
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02.04.
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	26.03.
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team	26.03.
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	26.03.
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	26.03.
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?	05.03.
Rocket Pharmaceuticals Q4 Loss Narrows	26.02.
Rocket Pharmaceuticals: Q4 Earnings Snapshot	26.02.
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	26.02.
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26.02.
North American Morning Briefing : S&P 500 Futures -2-	23.02.
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I	14.02.
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	13.02.
FDA Extends Review of Rocket Pharma's Proposed Kresladi	13.02.
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)	13.02.
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	13.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Rocket Pharmaceuticals, Inc.

Aktien

A2JA9Q

US77313F1066

RCKT

Andere Sprachen

Filter